|
GSK ills symptomatic of wider malaise
Financial Times The US Food and Drug Administration in 2000 authorised Advair, which combines two drugs and is breathed in with an inhaler, for long-term maintenance treatment of asthma, not for those with mild intermittent attacks. Yet the US court filings cite … |
View full post on asthma – Google News